Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
7
×
detroit blog main
detroit top stories
indiana blog main
7
×
indiana top stories
merck
7
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
life sciences
fda
cancer
clinical trials
abbvie
abeona therapeutics
affordable care act
cancer immunotherapy
deals
drug price
eli lilly
immunotherapy
What
bio
7
×
roundup
nash
drug
industry
policy
american
based
best
companies
continue
crash
debate
growing
healthcare
kind
new
news
people
pharmaceutical
politicians
pressure
scalps
trump’s
u.s
advantages
alliance
approval
approved
bar
biogen’s
biopharma
biopharmaceutical
brings
bristol
buy
calls
car
celgene
changing
Language
unset
Current search:
bio
×
photo
×
" indiana blog main "
×
merck
×
" bristol-myers squibb "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More